Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Celgene Continues Its Buying Spree

by | Jul 20, 2015 3:37 pm | Biotechnology

Celgene Corporation (NASDAQ: CELG) made yet another major acquisition last week, picking up Receptos, Inc. (NASDAQ: RCPT) for $7.2 billion. The acquisition significantly boosts Celgene’s Inflammation and Immunology portfolio with the addition of Receptos’ lead product candidate, Ozanimod, which is in Phase 3 tests to treat immune-inflammatory indications in irritable bowel syndrome and relapsing multiple sclerosis. This is Celgene’s biggest deal in 2015, out of the six it has announced. So far, the drug maker has splurged nearly $8.8 billion on acquisitions, collaborations with other drug makers and licensing deals. Read More »

Q2:15 Hospital M&A Stayed Active

by | Jul 20, 2015 3:35 pm | Hospitals

Hospital mergers and acquisitions didn’t flag in the second quarter of 2015, with at least 23 “definitive agreements” signed. That’s equal to the 23 recorded in the first quarter of the year. (We wait until hospital transactions get that far in the process, because so many fall apart after they sign a letter of intent.) Ventas Inc.’s (NYSE: VTR) $1.75 billion acquisition of Ardent Health Services was the biggest deal of the quarter, followed by Ventas’ expected spin-off of Ardent’s hospital operations to Equity Group Investments, LLC for $475 million. Watch for The Health Care M&A Report, Second Quarter 2015 to be published next week. Read More »

Long-Term Care Deals Still Piling Up

by | Jul 20, 2015 3:23 pm | Long-Term Care

Last week, eight more acquisitions were announced in the Long-Term Care sector, bringing the total to 22 transactions for July, so far. That’s a stronger pace than we’ve seen in recent months. The deal total for the seven deals that disclosed prices was just $220 million, about one-half of the $456 million spent on LTC acquisitions in July. In the second quarter of 2015, there were 64 publicly announced acquisitions in the seniors housing and care market, compared with 62 transactions in the year-ago quarter and 70 transactions in the first quarter of 2015. For second quarter activity, the 64 deals represent a record and implies we may be in for another strong second half of the year, much... Read More »

Molina Healthcare Steps Up Its Game

by | Jul 20, 2015 3:21 pm | Managed Care

The big buzz in the Managed Care sector is the $37 billion bid from Aetna (NYSE: AET) for Humana Inc. (NYSE: HUM), of course. While that deal is lauded for the Medicare assets it brings to Aetna, Molina Healthcare (NYSE: MOH) continues to beef up on Medicaid assets. Last week it announced two deals, one for the Medicaid assets of MyCare Chicago covering approximately 61,000 enrollees in Cook County, Illinois. The other was for Preferred Medical Plan’s Medicaid assets, serving approximately 25,000 enrollees. These deals come on the heels of its acquisition in May of HealthPlus of Michigan’s MIChild contract, with around 6,000 patients, and the Medicaid contract of HealthPlus Partners,... Read More »

BioClinica Acquires a Patient Recruitment Firm

by | Jul 13, 2015 3:08 pm | Other Services, Private Equity

BioClinica, Inc., a global provider of clinical trial management services, extended its offerings with the acquisition of MediciGroup, Inc., a global patient recruitment and retention firm. The acquisition includes MediciGlobal, Ltd. and Access to Patients, LLC. Medici also provides a lost-to-follow-up patient locate service that finds missing patients globally. BioClinica was taken private for $123 million in January 2013 by a joint venture between JLL Partners, Inc. and Ampersand Partners. As part of that deal, the firms paid an undisclosed amount for medical imaging company CoreLab Partners, Inc. and merged it with BioClinica. Financial terms for the MediciGroup deal were not disclosed.... Read More »

Consolidation Continues in the CRO Market

by | Jul 13, 2015 3:00 pm | Other Services

Back in 2013 clinical research organizations (CROs) were hot commodities, with 20 transactions for the year (that’s big, for the CRO sector). That was the summer that Kohlberg Kravis Roberts (NYSE: KKR) acquired PRA International and then ReSearch Pharmaceutical Services. This year, CROs are still in investors’ sites, with seven trasactions announced to date. After visiting a few healthcare deal making conferences recently, we expect to see a few more in the coming months. Read More »

Ventas Spins Off Ardent Health’s Hospital Operations

by | Jul 13, 2015 2:55 pm | Hospitals

As expected, Ventas, Inc. (NYSE: VTR) transferred the majority of Ardent Health Service’s hospital operations to Equity Group Investments last week, in exchange for $475 million. Ventas retains the owned real estate of the 10 Ardent Health hospitals, which it acquired in April 2015 for $1.75 billion. Ventas retains a 9.9% interest, while EGI and current Ardent Health Services management share the remaining ownership stake.   Read More »

Eye Diseases Spur More M&A in July

by | Jul 13, 2015 2:49 pm | Biotechnology, Medical Devices

At least three of the deals announced so far in July have targeted companies or compounds that treat eye diseases. The first was Biogen Inc. (NASDAQ: BIIB) and its $124 million deal with Applied Genetic Technologies (NASDAQ: AGTC) for the worldwide commercialization rights to one clinical-stage and one pre-clinical therapeutic program. Last week, Allergan Inc. (NYSE: AGN) paid $125 million for Oculeve, Inc., a medical device company focused on new technologies for dry eye disease. Then, rival Valeant Pharmaceuticals International (NYSE: VRX) paid an undisclosed amount for the global rights to EyeGate Pharmaceuticals’ (OTCQB: EYEG) EyeGate II Delivery System and EGP-437 combination product... Read More »